Donate today and join the fight to achieve global malaria elimination targets.
Together we can make a significant contribution to achieving malaria elimination targets.
Improving the health of vulnerable communities and changing lives is at the heart of what we do and who we are.
Multiple myeloma (MM) remains an incurable bone marrow cancer and is increasing in our ageing population.
Despite a new class of highly specific “drugs” called monoclonal antibodies (MAb) being extremely successful in the treatment of blood cancers like lymphoma, useful therapeutic MAb have not been produced for the treatment of MM.
We are using proteomic methods to discover new molecules on the surface of MM cells. These new proteins will form the targets for the production of MAb which may either interfere with MM cell growth, or harness the body’s natural defences to attack the MM cells, as has been successful in other lymphoma therapy.
We have discovered several candidate molecules.
For any general enquiries relating to this project, please contact:
Head, Immune Therapies Group
To create and translate knowledge into better health, so no-one is left behind.
85 Commercial Road, Melbourne
VIC, 3004, Australia
Receive updates and IMPACT magazine.
Copyright © 2022 Burnet Institute. ABN: 49 007 349 984
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung people and we offer our respects to their Elders past and present.
We recognise and respect the continuation of cultural, spiritual and educational practices of Aboriginal and Torres Strait Islander peoples of this land.
